Serimmune
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
150 Castilian Dr Ste 100, Goleta, Califo...Phone Number
(619) 203-5391Website
www.serimmune.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Serimmune
Serimmune is an immune intelligence company that decodes the complexity of human antibody responses, facilitating research biomarker discovery projects. Recently, it became part of Infinity Bio, Inc., enhancing its capabilities with advanced technologies in antibody reactome services. The integration aims to accelerate progress in immunology research and translational science while maintaining a commitment to scientific innovation and support. Serimmune continues to offer its powerful short epitope profiling and discovery platform, now with expanded resources.Explore more
Serimmune Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Serimmune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Serimmune had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Serimmune is spiking on competitors!
Funding: Get notified immidiatlly once Serimmune has new funding data
Check if Serimmune has recently received funding, and reach out quickly before it becomes old news!
Serimmune, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Serimmune launches new products
Earning: See what the market has to say on Serimmune recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Serimmune
Recommended Actions
Find VP level buyers at Serimmune
Find more new buyers
Compare Similar Companies to Serimmune
Compare insights from companies similar to Serimmune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Serimmune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Serimmune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Serimmune.
Serimmune financials insights
Gather financial insights about Serimmune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Private Equity
$2.5M
2017
Private Equity
$8M
Serimmune Tech Stack
A closer look at the technologies used by Serimmune
See more technologies
Serimmune News & Media
Serimmune to Lead Discussion on Advances in Vaccine Development at Vaccine Summit 2023
--(BUSINESS WIRE)--WHAT: Serimmune will discuss its Serum Epitope Repertoire Analysis (SERA) platform and how it can be applied in various studies to gain insight into past and present humoral immune responses in individuals and cohorts. The new vaccine development session will be led by Dr. John Shon and will review how SERA allows for the detection of an unlimited number of B cell immune responses in a single assay, enabling comparative immunomics and precision immunology.Serimmune Announces Use of Its SERA Platform in Study Designed to Identify Features of Long COVID Through Immune Profiling
GOLETA, Calif.--(BUSINESS WIRE)--Serimmune, a leader in understanding the antibody repertoire's role in human disease, announced today the publication of a study in Nature in which their proprietary Serum Epitope Repertoire Analysis (SERA) technology platform was one of the methods used to analyze the biological processes associated with the development and persistence of Long COVID symptoms, such as fatigue, brain fog and malaise. The cross-sectional study of 273 individuals, which included muSerimmune Announces Appointment of Dr. Gary Schroth to its Scientific Advisory Board
GOLETA, Calif.--(BUSINESS WIRE)--Serimmune, a leader in understanding the antibody repertoire’s role in human disease, announced today the appointment of Gary Schroth, PhD, Vice President and Distinguished Scientist at Illumina, to its Scientific Advisory Board (SAB). As an industry veteran in genomics and next-generation sequencing (NGS), Dr. Schroth brings more than 25 years of scientific and leadership experience to this role. At Illumina, he currently oversees the Core Applications Group inHHS and the Cohen Foundation Name Serimmune a Phase 1 Winner in LymeX Diagnostics Prize
GOLETA, Calif.--(BUSINESS WIRE)--The U.S. Department of Health and Human Services and the Cohen Foundation have selected Serimmune as a Phase 1 winner in the LymeX Diagnostics Prize, a LymeX Innovation Accelerator (LymeX) prize competition to accelerate the development of Lyme disease diagnostics. As a Phase 1 winner, Serimmune will receive $100,000 and an invitation to participate in a second phase. Serimmune’s solution, Serum Epitope Repertoire Analysis (SERA), is designed to utilize bacteria
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Serimmune
Sign Up For FreeTo access detailed company insights
Serimmune is an immune intelligence company that decodes the complexity of human antibody responses, facilitating research biomarker discovery projects. Recently, it became part of Infinity Bio, Inc., enhancing its capabilities with advanced technologies in antibody reactome services. The integration aims to accelerate progress in immunology resear... Read More
